MCDC Archives - EverGlade

MCDC Seeks Portable mNGS Solutions for Rapid Pathogen Detection

Leave a Comment / All Posts, CPE CBRND, Defense, Life Sciences / By Katie Cunningham, Growth Marketing Manager

MCDC-RFI-Agnostic-Metagenomic-Next-Generation-Sequencing-for-Clinical-Diagnostics Overview of Solicitation The Medical CBRN Defense Consortium (MCDC), managed by Advanced Technology International (ATI) in support of the Capability Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND), has released a Request for Information (RFI) titled Agnostic Metagenomic Next-Generation Sequencing (mNGS) for Clinical Diagnostics. Unlike traditional targeted assays, which require

MCDC Seeks Portable mNGS Solutions for Rapid Pathogen Detection Read More »

MCDC’s Host-Based Diagnostics for Acute Infections RFI

Leave a Comment / All Posts, CPE CBRND, Defense, Life Sciences / By Katie Cunningham, Growth Marketing Manager

MCDC Request for Information HOST-BASED DIAGNOSTICS Final A Shift Toward Host-Response Diagnostics The Medical CBRN Defense Consortium (MCDC), managed by Advanced Technology International (ATI), has released a Request for Information (RFI) titled Host-Based Diagnostics for Acute Infections. Issued in support of the Capability Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND),

MCDC’s Host-Based Diagnostics for Acute Infections RFI Read More »

MCDC Host-Directed Therapeutics Initiative

MCDC’s Host-Directed Therapeutics Initiative

Leave a Comment / All Posts, CPE CBRND, Defense, Life Sciences / By Max Higgins, Senior Consultant

The Medical Chemical, Biological, Radiological, and Nuclear Defense Consortium (MCDC), managed by Advanced Technology International (ATI), has issued a Request for Information (RFI) focused on “Host-Directed Medical Countermeasures.” This effort, led in support of the Capability Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND), represents an early step toward shaping a

MCDC’s Host-Directed Therapeutics Initiative Read More »